Evidence map›Paper›PMID 29168107›Full record

Observational studyClinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico2018

Predictive factors of trastuzumab-based chemotherapy in HER2 positive advanced gastric cancer: a single-center prospective observational study.

Q Li, H Li, H Jiang, Y Feng, Y Cui, Y Wang, Y Ji, Y Yu, W Li, C Xu and 3 more

Registry-linked trialAbstract readObservational Study
PubMed Publisher
In one paragraph

Observational study in Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03024450 (Efficacy and Prognostic Factors of Trastuzumab Based Therapy in HER2 Positive Advanced Gastric Cancer), which is not on this map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03024450 completednot on this map

Efficacy and Prognostic Factors of Trastuzumab Based Therapy in HER2 Positive Advanced Gastric Cancer: a Single Center Prospective Observational Study

Typeobservational_patient_registrySponsorShanghai Zhongshan HospitalRan2012 to 2016Enrolled98ConditionsGastric AdenocarcinomaArmsH+CT
3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Review
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Q LiDepartment of Medical Oncology, Shanghai Zhongshan Hospital, Fudan University, No. 180, Fenglin Rd, Xuhui District, Shanghai, 200032, China.
H LiDepartment of Medical Oncology, Shanghai Zhongshan Hospital, Fudan University, No. 180, Fenglin Rd, Xuhui District, Shanghai, 200032, China.
H JiangDepartment of Medical Oncology, Shanghai Zhongshan Hospital, Fudan University, No. 180, Fenglin Rd, Xuhui District, Shanghai, 200032, China.
Y FengDepartment of Medical Oncology, Shanghai Zhongshan Hospital, Fudan University, No. 180, Fenglin Rd, Xuhui District, Shanghai, 200032, China.
Y CuiDepartment of Medical Oncology, Shanghai Zhongshan Hospital, Fudan University, No. 180, Fenglin Rd, Xuhui District, Shanghai, 200032, China.
Y WangDepartment of Medical Oncology, Shanghai Zhongshan Hospital, Fudan University, No. 180, Fenglin Rd, Xuhui District, Shanghai, 200032, China.
Y JiDepartment of Pathology, Zhongshan Hospital, Fudan University, Shanghai, China.
Y YuDepartment of Medical Oncology, Shanghai Zhongshan Hospital, Fudan University, No. 180, Fenglin Rd, Xuhui District, Shanghai, 200032, China.
W LiDepartment of Medical Oncology, Shanghai Zhongshan Hospital, Fudan University, No. 180, Fenglin Rd, Xuhui District, Shanghai, 200032, China.
C XuDepartment of Pathology, Zhongshan Hospital, Fudan University, Shanghai, China.
S YuDepartment of Medical Oncology, Shanghai Zhongshan Hospital, Fudan University, No. 180, Fenglin Rd, Xuhui District, Shanghai, 200032, China.
R ZhuangDepartment of Medical Oncology, Shanghai Zhongshan Hospital, Fudan University, No. 180, Fenglin Rd, Xuhui District, Shanghai, 200032, China.
T LiuDepartment of Medical Oncology, Shanghai Zhongshan Hospital, Fudan University, No. 180, Fenglin Rd, Xuhui District, Shanghai, 200032, China. liu.tianshu@zs-hospital.sh.cn.ORCID http://orcid.org/0000-0002-8604-6311

Funding

Shanghai Association for Science and Technology (CN) 15411961900
6 · The paper itself

Abstract

purposeTrastuzumab plus chemotherapy is an effective therapy in HER2 positive advanced gastric cancer (AGC). However, the clinicopathologic factors that predict the outcome of routine trastuzumab therapy remain unclear.

methodsThe outcome and safety profile of trastuzumab therapy in untreated HER2 positive AGC was evaluated in this prospective observational study. Clinical and pathological data including demographics, treatment profiles, expression level of HER2 were analyzed to identify predictive factors of trastuzumab-based first-line therapy for their progression-free survival (PFS).

resultsOverall, 107 patients were eligible. The median number of treatment cycles was 9 (range 1-44), the median PFS and median overall survival (OS) were 7.7 months (95% CI 6.5-8.9) and 16.0 months (95% CI 13.2-18.8), respectively. The confirmed response rate was 58.9%, and the disease control rate was 82.2%. Patients with liver metastasis (HR 1.616) and poor performance status (PS, HR 2.518) were independently associated with a worse PFS, while the other clinicopathological factors including demographics, treatment profiles and some other clinical characteristics did not predict the survival.

conclusionsIn routine clinical practice, the addition of trastuzumab to chemotherapy was effective and safe in real-world setting in Chinese patients with HER2 positive AGC, regardless of most of the clinicopathological factors. Further studies are needed to improve the prognosis of HER2 positive patients with liver metastasis or poor PS. Trial Registration clinicaltrials.gov Identifier: NCT03024450.

Indexed as

Antineoplastic Agents, ImmunologicalErb-b2 Receptor Tyrosine KinasesStomach NeoplasmsTrastuzumabAdultAgedAged, 80 and overFemaleFollow-Up StudiesHumansMaleMiddle AgedPrognosisProspective StudiesSurvival RateAntineoplastic Agents, ImmunologicalErb-b2 Receptor Tyrosine KinasesTrastuzumabGastric cancerHER2Predictive factorsTrastuzumab

Identifiers

PMID29168107

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.